Table 1

Patients’ demographic characteristics, clinical diagnoses, anatomical sites injected, dose of triamcinolone acetonide, and baseline and follow up clinical and sonographic scores

PatientAge (years)SexAnatomical siteDiagnosisDose of triamcinolone acetonide (mg)BaselineFollow up after 2 weeks
VAS (0–10)Tenderness (0–3)GSS (1–4)PDS (1–4)VAS* (0–10)Tenderness* (0–3)GSS* (1–4)PDS* (1–4)
*p<0.01.
GSS, grey scale ultrasonography; PDS, power Doppler ultrasonography; RA, rheumatoid arthritis; PsA, psoriatic arthritis; ReA, reactive arthritis; CPPD, calcium pyrophosphate deposition disease; MTP, metatarsophalangeal joint; MCP, metacarpophalangeal joint; PIP, proximal interphalangeal joint; DIP, distal interphalangeal joint.
130FWristReA2082220011
232FWristRA2082332121
381MWristCPPD3052443133
482FWristRA3093341112
564FMTPRA10103224222
663FMTPRA10103444232
730FWristRA2072230011
854FMCPPsA1073224211
955FWristRA30103114211
1082FMCPRA1083230121
1168FWristRA3093234222
1263FWristRA3083443132
1362FWristRA3052243122
1437FPIPPsA10103341121
1570MWristCPPD3083214221
1670FWristCPPD3083231111
1730MDIPPsA1083240011
1831MDIPPsA1063222111
1930MWristPsA2083340011
2055FWristRA2062330121
Median58, 515F/5M83232121